^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Hemady (dexamethasone tablets)
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Dexcel Pharma
Drug class:
GCR agonist
Related drugs:
3d
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients with Refractory Multiple Myeloma (clinicaltrials.gov)
P2, N=38, Completed, Mayo Clinic | Active, not recruiting --> Completed
Trial completion
|
pomalidomide • Empliciti (elotuzumab) • Hemady (dexamethasone tablets) • dexamethasone injection
12d
AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov)
P3, N=5949, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Oct 2025
Trial completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6)
|
MLL rearrangement • MLL rearrangement
|
dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
12d
AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov)
P3, N=847, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2025
Trial completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD22 (CD22 Molecule) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule) • MPO (Myeloperoxidase)
|
CD22 expression
|
cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
18d
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov)
P3, N=158, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Sep 2025
Trial completion date
|
FLT3 (Fms-related tyrosine kinase 3) • RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
|
FLT3 mutation • FLT3 wild-type
|
cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
26d
AALL1821: A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
P2, N=300, Suspended, National Cancer Institute (NCI) | N=550 --> 300
Enrollment change • Combination therapy • Checkpoint inhibition
|
CD19 (CD19 Molecule)
|
CD19 expression
|
Opdivo (nivolumab) • cytarabine • Blincyto (blinatumomab) • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Hemady (dexamethasone tablets) • ABP 206 (nivolumab biosimilar) • Asparec (PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase) • Starasid (cytarabine ocfosfate) • dexamethasone injection
1m
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (clinicaltrials.gov)
P2, N=171, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2027 --> Dec 2028 | Initiation date: Oct 2024 --> Jan 2025 | Trial primary completion date: Dec 2027 --> Dec 2028
Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy
|
MCL1 (Myeloid cell leukemia 1) • KMT2A (Lysine Methyltransferase 2A) • BCL2L1 (BCL2-like 1)
|
BCL2 expression
|
Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • prednisolone
2ms
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) (clinicaltrials.gov)
P2/3, N=378, Not yet recruiting, SWOG Cancer Research Network
New P2/3 trial
|
docetaxel • Cyramza (ramucirumab) • Libtayo (cemiplimab-rwlc) • Hemady (dexamethasone tablets)
2ms
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients with Refractory Multiple Myeloma (clinicaltrials.gov)
P2, N=38, Active, not recruiting, Mayo Clinic | Trial completion date: Oct 2025 --> Oct 2024 | Trial primary completion date: Oct 2024 --> Feb 2024
Trial completion date • Trial primary completion date
|
pomalidomide • Empliciti (elotuzumab) • Hemady (dexamethasone tablets) • dexamethasone injection
2ms
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma (clinicaltrials.gov)
P1, N=0, Withdrawn, City of Hope Medical Center | N=21 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
Hemady (dexamethasone tablets) • azeliragon (TTP488) • dexamethasone injection
3ms
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial (clinicaltrials.gov)
P2, N=200, Not yet recruiting, Emory University | Initiation date: Jul 2024 --> Oct 2024
Trial initiation date
|
Hemady (dexamethasone tablets) • dexamethasone injection
4ms
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma (clinicaltrials.gov)
P2, N=34, Recruiting, Emory University | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025
Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
pomalidomide • Blenrep (belantamab mafodotin-blmf) • Hemady (dexamethasone tablets)
4ms
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma (clinicaltrials.gov)
P1, N=35, Terminated, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Jul 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Jul 2024; Inadequate accrual rate
Trial completion date • Trial termination • Trial primary completion date • Combination therapy
|
TP53 (Tumor protein P53) • CD4 (CD4 Molecule)
|
lenalidomide • carfilzomib • navtemadlin (KRT-232) • Hemady (dexamethasone tablets)
4ms
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
P1/2, N=4, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=40 --> 4
Enrollment closed • Enrollment change
|
IL3RA (Interleukin 3 Receptor Subunit Alpha)
|
Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • Elzonris (tagraxofusp-erzs) • mercaptopurine • mesna • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
4ms
AALL1631: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P3; Recruiting --> Active, not recruiting
Combination therapy • Enrollment closed • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • IKZF1 (IKAROS Family Zinc Finger 1) • CSF1R (Colony stimulating factor 1 receptor)
|
TruSight RNA Pan-Cancer Panel
|
imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • dexrazoxane
4ms
AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P3, N=218, Completed, Children's Oncology Group | Active, not recruiting --> Completed
Trial completion
|
cytarabine • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • lestaurtinib (CEP-701) • mercaptopurine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Neupogen (filgrastim) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)
5ms
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis (clinicaltrials.gov)
P3, N=338, Recruiting, SWOG Cancer Research Network | Not yet recruiting --> Recruiting
Enrollment open
|
CD34 (CD34 molecule)
|
bortezomib • cyclophosphamide • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection
5ms
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (clinicaltrials.gov)
P1, N=24, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
Trial completion date • Trial primary completion date • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • SDC1 (Syndecan 1) • BAX (BCL2-associated X protein)
|
Venclexta (venetoclax) • Ninlaro (ixazomib) • Hemady (dexamethasone tablets)
6ms
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib (clinicaltrials.gov)
P2, N=165, Active, not recruiting, Mayo Clinic | N=108 --> 165
Enrollment change
|
bortezomib • cyclophosphamide • Ninlaro (ixazomib) • Darzalex (daratumumab) • Hemady (dexamethasone tablets) • dexamethasone injection
6ms
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (clinicaltrials.gov)
P1, N=24, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Jun 2025 | Trial primary completion date: Sep 2024 --> Jun 2025
Trial completion date • Trial primary completion date • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • SDC1 (Syndecan 1) • BAX (BCL2-associated X protein)
|
Venclexta (venetoclax) • Ninlaro (ixazomib) • Hemady (dexamethasone tablets)
6ms
Radiosurgery Before Surgery for the Treatment of Brain Metastases (clinicaltrials.gov)
P1, N=20, Recruiting, Emory University | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Jan 2025
Trial completion date • Trial primary completion date • Surgery
|
Hemady (dexamethasone tablets) • dexamethasone injection
6ms
NCI-2018-01103: Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer (clinicaltrials.gov)
P2/3, N=99, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2026 --> Dec 2025 | Trial primary completion date: May 2026 --> Dec 2025
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Hemady (dexamethasone tablets)
6ms
Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov)
P2, N=26, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Sep 2025 | Trial primary completion date: Nov 2024 --> Sep 2025
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
Hemady (dexamethasone tablets) • dexamethasone injection
6ms
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=12, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> May 2024
Trial completion • Trial completion date • Combination therapy
|
carfilzomib • Reolysin (pelareorep) • Hemady (dexamethasone tablets) • dexamethasone injection
7ms
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) (clinicaltrials.gov)
P2, N=0, Withdrawn, National Cancer Institute (NCI) | N=154 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • navitoclax (ABT 263) • Oncaspar liquid (pegaspargase) • nelarabine • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
7ms
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (clinicaltrials.gov)
P2, N=137, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2024
Trial completion • Trial completion date • Combination therapy
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • Adcetris (brentuximab vedotin) • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • methotrexate IV
7ms
NCI-2018-01103: Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer (clinicaltrials.gov)
P2/3, N=99, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2024 --> May 2026 | Trial primary completion date: May 2024 --> May 2026
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Hemady (dexamethasone tablets)
7ms
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (clinicaltrials.gov)
P2, N=171, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Jul 2024
Trial initiation date • Combination therapy
|
MCL1 (Myeloid cell leukemia 1) • KMT2A (Lysine Methyltransferase 2A) • BCL2L1 (BCL2-like 1)
|
BCL2 expression
|
Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • prednisolone
7ms
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) (clinicaltrials.gov)
P2, N=154, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Aug 2024
Trial initiation date
|
Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • navitoclax (ABT 263) • Oncaspar liquid (pegaspargase) • nelarabine • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
7ms
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial (clinicaltrials.gov)
P2, N=200, Not yet recruiting, Emory University | Initiation date: Mar 2024 --> Jul 2024
Trial initiation date
|
Hemady (dexamethasone tablets) • dexamethasone injection
8ms
AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov)
P3, N=1895, Active, not recruiting, National Cancer Institute (NCI)
Trial completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD22 (CD22 Molecule) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule) • MPO (Myeloperoxidase)
|
CD22 expression
|
cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexamethasone injection
8ms
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis (clinicaltrials.gov)
P3, N=338, Not yet recruiting, SWOG Cancer Research Network | Initiation date: Oct 2023 --> May 2024
Trial initiation date
|
CD34 (CD34 molecule)
|
bortezomib • cyclophosphamide • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection
8ms
SWOG S0777: Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (clinicaltrials.gov)
P3, N=525, Active, not recruiting, National Cancer Institute (NCI)
Trial completion date
|
lenalidomide • bortezomib • Hemady (dexamethasone tablets)
8ms
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
P2, N=80, Recruiting, Mayo Clinic | N=55 --> 80
Enrollment change
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
|
IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation
|
cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection
8ms
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=38, Not yet recruiting, Thomas Martin, MD
New P1 trial
|
Talvey (talquetamab-tgvs) • iberdomide (CC-220) • Hemady (dexamethasone tablets)
8ms
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma (clinicaltrials.gov)
P1/2, N=5, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Mar 2024 | Trial primary completion date: May 2025 --> Mar 2024
Trial completion • Trial completion date • Trial primary completion date
|
lenalidomide • Darzalex (daratumumab) • Blenrep (belantamab mafodotin-blmf) • Hemady (dexamethasone tablets)
8ms
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (clinicaltrials.gov)
P2, N=171, Not yet recruiting, National Cancer Institute (NCI)
New P2 trial • Combination therapy
|
MCL1 (Myeloid cell leukemia 1) • KMT2A (Lysine Methyltransferase 2A) • BCL2L1 (BCL2-like 1)
|
BCL2 expression
|
Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • prednisolone
8ms
Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or CCUS (clinicaltrials.gov)
P2, N=55, Recruiting, Mayo Clinic | Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
|
IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation
|
cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • dexamethasone injection
9ms
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
P2, N=70, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Feb 2025 --> Sep 2026 | Initiation date: Feb 2024 --> Nov 2024 | Trial primary completion date: Feb 2025 --> Sep 2026
Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
|
lenalidomide • bortezomib • Xpovio (selinexor) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets)
9ms
Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma (clinicaltrials.gov)
P1, N=100, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
Chr t(11;14)
|
Venclexta (venetoclax) • lenalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets)
9ms
AALL1732: Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (clinicaltrials.gov)
P3, N=4997, Recruiting, Children's Oncology Group | Trial completion date: Jun 2029 --> Mar 2030 | Trial primary completion date: Jun 2029 --> Mar 2030
Trial completion date • Trial primary completion date
|
cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
9ms
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma (clinicaltrials.gov)
P2, N=17, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=190 --> 17
Enrollment closed • Enrollment change • Combination therapy • Immunomodulating
|
lenalidomide • pomalidomide • Hemady (dexamethasone tablets)
9ms
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients With Glioblastoma (clinicaltrials.gov)
P1, N=21, Suspended, City of Hope Medical Center | Not yet recruiting --> Suspended
Trial suspension
|
Hemady (dexamethasone tablets) • azeliragon (TTP488) • dexamethasone injection
Share via
